Company Performance Metrics
SiBiono is a pioneer in the field of gene therapy industry in China. The self-developed product recombinant Ad-p53 adenovirus injection (now Gendicine) was awarded the new drug certificate issued by the State Food and Drug Administration on October 16, 2003, and was produced on January 20, 2004. Approved, passed the drug GMP certification on March
11, 2004, becoming the world's first new gene therapy drug that has been officially approved for marketing, making gene therapy a new treatment for cancer therapy. The birth of "this life is born again" is an important representative of China's independent innovation in science and technology. It is regarded as a milestone for China to catch up with the West and has received worldwide attention. With its strong R&D capabilities, Cybino has undertaken a number of national biotech projects, including the National 973 Program 863 Program, the National Tenth Five-Year National Science and Technology Project, the National Innovation Fund Project, and the National Ninth Five-Year Plan. Local government's high-tech industry plan. Up to now, the company has applied for 7 relevant invention patents for independent innovation achievements, involving key intellectual property rights such as product invention, production process invention.
